You have been taking the pills religiously. Tranexamic acid, 250 mg twice a day. Vitamin C, 1000 mg every morning. Maybe glutathione capsules too, because someone on a skincare forum swore by them. You protect your skin from the sun. You follow all the advice.

And yet, six months later, the patches on your cheeks are still there. Perhaps slightly lighter, perhaps unchanged, perhaps stubbornly persistent despite your disciplined compliance.

You are not doing anything wrong. You are encountering the fundamental limitation of oral medications for a condition that exists in a very specific, localized tissue environment. Melasma is not a systemic disease that responds well to systemic treatment. It is a local microenvironment problem that requires local solutions.

Table of Contents

• The Appeal of Oral Melasma Medications

• Tranexamic Acid: What It Can and Cannot Do

• Vitamin C and Antioxidants: The Bioavailability Problem

• The Pharmacological Gap: Systemic Delivery vs. Local Need

• Oral Medications vs. Targeted Local Delivery: A Comparison

• When Oral Medications Have a Role and When They Do Not

The Appeal of Oral Melasma Medications

The popularity of oral treatments for melasma is entirely understandable. They are easy to take, require no clinic visits, carry no risk of procedural complications, and feel like a natural, gentle approach. In a landscape where patients have been burned by aggressive laser treatments or irritated by potent topical creams, the idea of healing from the inside out is deeply appealing.

Oral tranexamic acid in particular has generated significant excitement since studies from East Asian dermatology groups demonstrated its efficacy in randomized controlled trials. The evidence is real: tranexamic acid does reduce melasma severity scores compared to placebo, typically in the range of a 25-50% reduction in MASI scores over twelve weeks.

Vitamin C (ascorbic acid), glutathione, and other antioxidant supplements have a more mixed evidence base but are widely used based on their known roles in melanin synthesis pathways. Vitamin C inhibits tyrosinase and has antioxidant properties that may reduce oxidative stress-driven melanogenesis. Glutathione shifts melanin production from the darker eumelanin toward the lighter pheomelanin.

The question is not whether these agents have biological activity against melanogenesis. They do. The question is whether oral administration can deliver sufficient concentrations to the specific tissue where melasma occurs to produce clinically meaningful and lasting results.

Tranexamic Acid: What It Can and Cannot Do

Tranexamic acid is a synthetic lysine analog that inhibits plasminogen activator, reducing the conversion of plasminogen to plasmin. In the context of melasma, its proposed mechanism involves suppressing keratinocyte production of prostaglandins and arachidonic acid, both of which stimulate melanocyte activity. It also reduces the interaction between keratinocytes and melanocytes by blocking the plasminogen/plasmin system that mediates their crosstalk.

Additionally, tranexamic acid has anti-angiogenic properties that may help normalize the increased dermal vascularity observed in melasma lesions. This vascular component is significant because abnormal blood vessels in melasma skin produce factors that directly stimulate melanocytes.

These are meaningful mechanisms. The limitation is one of concentration and precision. When you take 250 mg of tranexamic acid orally, it enters your bloodstream and distributes throughout your entire body. The amount that reaches the specific square centimeters of facial skin where your melasma resides is a tiny fraction of the ingested dose.

Pharmacokinetic studies of oral tranexamic acid show that peak plasma concentrations occur approximately two to three hours after ingestion, with a bioavailability of about 30-50%. From the plasma, the drug must then distribute into the skin tissue, crossing from capillaries into the extracellular space of the dermis and epidermis. The actual tissue concentration achieved in the melasma-affected areas is orders of magnitude lower than the plasma concentration.

This explains the clinical observation that oral tranexamic acid produces partial but usually incomplete improvement. It delivers enough drug to modestly suppress some melanogenic pathways but not enough to fully overcome the powerful local signals driving pigment production. And when the medication is stopped, even this partial suppression disappears, and the melasma typically returns to its pre-treatment severity within two to six months.

There is also the question of long-term safety. Tranexamic acid is an antifibrinolytic agent, meaning it inhibits the breakdown of blood clots. While the low doses used for melasma (250-500 mg daily) are well below the doses used for hemostatic indications, there have been case reports of thromboembolic events in patients taking oral tranexamic acid for melasma, particularly in those with pre-existing risk factors such as oral contraceptive use, smoking, personal or family history of thrombosis, or prolonged immobility. This risk profile limits the population that can safely use the medication long-term.

Vitamin C and Antioxidants: The Bioavailability Problem

The bioavailability challenge is even more pronounced with vitamin C. Oral ascorbic acid absorption follows a saturable, dose-dependent mechanism. At doses of 200 mg, bioavailability approaches 100%. At 1000 mg, the dose most commonly taken by melasma patients, bioavailability drops to approximately 50%. At 2000 mg, it falls further, with the excess excreted in urine.

Once absorbed, vitamin C is distributed to every tissue in the body according to metabolic demand. Organs with high metabolic activity, such as the adrenal glands, brain, and eyes, preferentially sequester vitamin C. The skin receives a proportionally smaller share, and within the skin, there is no mechanism for selective accumulation in melasma-affected areas versus normal skin.

Studies measuring skin ascorbic acid levels after oral supplementation show that even with maximal oral dosing, the achievable tissue concentration is insufficient to produce significant tyrosinase inhibition. For comparison, topical vitamin C formulations deliver concentrations to the skin that are twenty to forty times higher than what oral supplementation can achieve. And even topical vitamin C at these higher concentrations produces only modest improvements in melasma.

Glutathione presents similar challenges. Oral glutathione is extensively degraded in the gastrointestinal tract before absorption. Sublingual and liposomal formulations claim better bioavailability, but even these deliver minimal concentrations to specific skin areas. Intravenous glutathione bypasses the absorption issue but raises its own safety concerns and also lacks evidence for sustained efficacy in melasma.

The fundamental issue across all these supplements is the same: the body does not have a mechanism for selectively concentrating these agents in melasma-affected skin. Oral administration treats the entire body when the problem is in a few square centimeters of facial tissue.

The Pharmacological Gap: Systemic Delivery vs. Local Need

To understand why oral medications underperform in melasma, consider an analogy. Imagine trying to water a single wilting plant in a vast garden by turning on a sprinkler that covers the entire garden equally. The wilting plant gets some water, but the vast majority goes to soil that does not need it. You could increase the sprinkler output, but that risks waterlogging the rest of the garden (systemic side effects) while still delivering only marginally more to the target plant.

This is essentially what happens with oral melasma medications. The drug distributes everywhere, achieving therapeutic levels nowhere specifically. The concentration at the melasma lesion is governed by general tissue distribution kinetics, not by any targeting mechanism.

This pharmacological gap is why dermatology research has increasingly focused on local delivery methods for melasma. Topical formulations improve on oral delivery by concentrating the agent at the skin surface, but they face their own limitation: penetration through the stratum corneum barrier limits how much active agent reaches the deeper layers where much of the melanocyte dysregulation occurs, particularly in dermal and mixed-type melasma.

Injectable approaches represent the logical next step in this progression. By delivering therapeutic agents directly to the dermal-epidermal junction through microinjection, the Melasma Injection Treatment approach bypasses both the systemic dilution problem of oral medications and the penetration barrier problem of topical formulations. The full administered dose reaches the exact tissue where it is needed.

Oral Medications vs. Targeted Local Delivery: A Comparison

When Oral Medications Have a Role and When They Do Not

Despite their limitations, oral medications are not without value in melasma management. Their role should be understood accurately: they are adjunctive, not curative.

Where oral tranexamic acid is reasonable: As a supporting component of a multimodal treatment plan that includes locally targeted therapy and rigorous sun protection. It may provide additional, incremental benefit beyond what local treatment alone achieves. It is particularly useful in patients with widespread melasma affecting large areas where injection therapy would require extensive treatment. It serves as a reasonable bridge therapy while awaiting locally targeted treatment.

Where oral tranexamic acid is insufficient: As monotherapy for melasma. In patients who need significant visible improvement. For patients who cannot tolerate the medication long-term. When the melasma is predominantly dermal type, since the drug's ability to reach dermal melanocytes at therapeutic concentrations is particularly limited. In patients with thromboembolic risk factors.

Where vitamin C and antioxidant supplements have value: General skin health support and photoprotection enhancement. Systemic antioxidant benefits that may support overall skin resilience. Adjunctive support alongside targeted local treatments.

Where vitamin C and antioxidants are insufficient: As treatments for established melasma patches. When used alone without local therapy and sun protection. When patients expect visible lightening from supplements alone.

The honest assessment is that oral medications for melasma represent an intellectually appealing concept, targeting melanogenesis from the inside, that is limited by the pharmacological realities of systemic drug distribution. Patients deserve to understand these limitations upfront rather than spending months or years on oral regimens that cannot, by their pharmacological nature, deliver the results they are hoping for.

If you have been taking oral medications for melasma without satisfactory results, the issue is likely not compliance or patience. It is that the treatment modality has reached its inherent ceiling. A Melasma Injection Treatment consultation can help determine whether a targeted local approach might achieve what systemic therapy could not.

Frequently Asked Questions

Q1: Should I stop taking oral tranexamic acid if I start injection treatment?

This depends on your individual treatment plan and should be decided in consultation with your treating physician. In some cases, oral tranexamic acid is continued during injection therapy as a complementary systemic support. In other cases, it may be tapered and discontinued once the locally targeted treatment demonstrates sufficient effect. The goal is to minimize unnecessary medication use while maximizing treatment benefit.

Q2: I have been taking tranexamic acid for a year. Is it safe to continue indefinitely?

Long-term safety data for oral tranexamic acid at melasma doses (250-500 mg daily) beyond one to two years is limited. While many patients tolerate it well, the theoretical risk of thromboembolic events exists. Regular reassessment with your prescribing physician is essential, including discussion of risk factors such as smoking, oral contraceptive use, family history of clotting disorders, and recent surgery or prolonged immobility. If your melasma is not well-controlled despite a year of oral therapy, continuing indefinitely without adding or switching to a more targeted approach may not be the best strategy.

Q3: Are higher doses of vitamin C more effective for melasma?

No. Vitamin C absorption follows saturable kinetics, meaning that increasing the oral dose beyond approximately 200 mg does not proportionally increase tissue levels. Doses above 1000 mg primarily increase urinary excretion and gastrointestinal side effects without meaningfully increasing skin concentrations. If you want to deliver more vitamin C to your skin, topical application is more effective than increasing oral dose, though even topical vitamin C has limited efficacy for melasma as monotherapy.

Q4: My melasma improved initially on tranexamic acid but has plateaued. Does this mean it stopped working?

This plateau effect is common and reflects the ceiling of what systemic delivery can achieve. The initial improvement likely represents the suppression of the most drug-responsive component of your melasma. The remaining pigmentation is driven by factors that the systemically available drug concentration cannot adequately address, such as deep dermal pigment, structural basement membrane disruption, or established vascular changes. The medication is still working at its maximal capacity; it is the capacity itself that is limited.

Q5: Are there newer oral medications for melasma that work better than tranexamic acid?

Research continues into various oral agents including polypodium leucotomos extract, melatonin, and various anti-inflammatory compounds. While some show promise in early studies, none have demonstrated dramatically superior efficacy to tranexamic acid. The fundamental limitation of systemic delivery for a localized condition applies regardless of which specific drug is used. The most promising advances in melasma treatment are in local delivery methods rather than new oral agents.

Q6: Can injection therapy work for someone who did not respond to oral medications?

Yes. The reason oral medications may fail is not that the patient is "treatment-resistant" in some absolute sense, but rather that the drug did not reach the target tissue in sufficient concentration. The Melasma Injection Treatment approach bypasses the pharmacological bottleneck of systemic distribution by delivering therapeutic agents directly to the affected tissue. Many patients who see incomplete results with oral therapy respond favorably to targeted local delivery, precisely because the treatment reaches the microenvironment that drives the disease.

About the Author

Dr. Liu Ta-Ju is the founder of Liusmed Clinic, a specialized center for regenerative medicine and minimal incision surgery in Taiwan. Dr. Liu's approach to melasma treatment is grounded in an understanding of pharmacological delivery science, recognizing that the route of administration is often as important as the choice of therapeutic agent. His clinic specializes in targeted local delivery methods for patients who have not achieved satisfactory results with conventional systemic or topical treatments.

Disclaimer

This article is provided for educational and informational purposes only and does not constitute medical advice. Do not alter your prescribed medication regimen without consulting your treating physician. Individual skin conditions vary significantly, and treatment outcomes depend on numerous patient-specific factors. Always consult a qualified dermatologist or medical professional before making decisions about melasma treatment. The information presented here reflects current medical understanding as of the publication date and may be updated as new research becomes available.

{

"@context": "https://schema.org",

"@type": "MedicalWebPage",

"headline": "Taking Vitamin C and Tranexamic Acid but Still Getting Spots? The Limits of Oral Medications for Melasma",

"description": "Oral tranexamic acid and vitamin C supplements are popular adjunctive treatments for melasma, but many patients find they cannot achieve satisfactory results with oral medications alone. Understand the pharmacological limitations and why systemic delivery may not reach where it matters most.",

"author": {

"@type": "Person",

"name": "Dr. Liu Ta-Ju",

"affiliation": {

"@type": "MedicalClinic",

"name": "Liusmed Clinic"

}

},

"datePublished": "2026-02-28",

"publisher": {

"@type": "MedicalClinic",

"name": "Liusmed Clinic",

"url": "https://liusmed.com"

},

"medicalAudience": {

"@type": "PatientAudience",

"audienceType": "Patient"

},

"about": {

"@type": "MedicalCondition",

"name": "Melasma"

},

"mainEntityOfPage": {

"@type": "WebPage",

"@id": "https://liusmed.com/articles/repair/oral-vitamins-tranexamic-acid-limits"

}

}

-->